Orchard Software Announces New Electronic Support for Antimicrobial Stewardship
CARMEL, Ind., April 4, 2024 /PRNewswire/ -- Today, Orchard Software announced the availability of Antimicrobial Use and Resistance (AUR) reporting to the National Healthcare Safety Network (NHSN), wh
PR NewswireApr 4 11:23 ET
Orchard Therapeutics Announces Launch Plans For Lenmeldy - Quick Facts
RTTNewsMar 20 08:05 ET
Orchard Therapeutics Receives FDA Approval of Lenmeldy (Atidarsagene Autotemcel), the Only Therapy for Eligible Children With Early-onset Metachromatic Leukodystrophy in the U.S.
Orchard Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).
GlobeNewswireMar 18 15:41 ET
ORI Capital Raises $260 Million for Second Life Sciences Fund
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
BusinesswireFeb 22 08:00 ET
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to
GlobeNewswireFeb 5 07:00 ET
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients
GlobeNewswireFeb 2 07:00 ET
Express News | Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (Atidarsagene Autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)
Moomoo 24/7Jan 25 07:16 ET
Orchard Therapeutics Announces Agreement With the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy
GlobeNewswireJan 25 07:00 ET
Orchard Therapeutics Announces Board Reshuffle Following Transaction
TipRanksJan 25 04:32 ET
Orchard Therapeutics' Shareholder Rights Altered Post-Acquisition
TipRanksJan 25 04:32 ET
Orchard Therapeutics ADSs Delisting From Nasdaq
TipRanksJan 25 04:32 ET
Orchard Therapeutics Acquired by Kyowa Kirin
TipRanksJan 25 04:32 ET
Orchard Therapeutics Ends Key Financial Agreement Post-Transaction
TipRanksJan 25 04:31 ET
News On Orchard Therapeutics PLC (ORTX) Now Under 4151.TO
News On Orchard Therapeutics PLC (ORTX) Now Under 4151.TO
Dow JonesJan 24 17:08 ET
Orchard Therapeutics Becomes Wholly-Owned Subsidiary of Kyowa Kirin >ORTX
Orchard Therapeutics Becomes Wholly-Owned Subsidiary of Kyowa Kirin >ORTX
Dow JonesJan 24 05:05 ET
Kyowa Kirin: Acquisition Was Completed Wednesday >ORTX
Kyowa Kirin: Acquisition Was Completed Wednesday >ORTX
Dow JonesJan 24 05:05 ET
Kyowa Kirin Successfully Completes Acquisition Of Orchard Therapeutics, A Global Gene Therapy Leader For Rare Diseases ORTX
Kyowa Kirin Successfully Completes Acquisition Of Orchard Therapeutics, A Global Gene Therapy Leader For Rare Diseases ORTX
Dow JonesJan 24 05:00 ET
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection With Merger With NAYA Biosciences, NAYA Announces New Board Directors
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate
GlobeNewswireJan 17 08:00 ET
Catalyst Watch: Spotlight on FedEx, Nike, Micron and Gold Stocks
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out.
Seeking AlphaDec 15, 2023 15:10 ET
Orchard Therapeutics' Gene Therapy Gets Swiss Regulatory Approval
Gene therapy company Orchard Therapeutics (OT10.F) said Monday the Swiss Agency for Therapeutic Products, Swissmedic, approved the use of its Libmeldy hematopoietic stem cell gene therapy in the count
MT NewswiresDec 11, 2023 10:58 ET
No Data
No Data